Stay updated on Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial page.

Latest updates to the Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial page
- CheckyesterdayChange DetectedA site-wide notice announces an NIH website transition and says that some NIH content will use “Super Intelligence” in place of “Artificial Intelligence”.SummaryDifference1%

- Check7 days agoChange DetectedThe ClinicalTrials.gov footer revision updated from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating the page is currently inaccessible.SummaryDifference19%

- Check42 days agoChange DetectedThe study page no longer displays the 'Melanoma' disease label or the 'MedlinePlus Genetics' related topics link, altering the disease context and available related resources on the page.SummaryDifference0.2%

- Check49 days agoChange DetectedMelanoma is added as a related topic and MedlinePlus Genetics as a related topic in the study’s metadata. This expands the contextual keywords and helps link the trial to related resources without changing the trial's substantive details.SummaryDifference0.2%

Stay in the know with updates to Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Helper Peptide Vaccine Plus Pembrolizumab Clinical Trial page.